Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01.
Yoshioka H, Ishida T, Atagi S, Tamiya A, Nishimura T, Iwamoto Y, Kanehara M, Kim YH, Korogi Y, Tomii K, Katakami N, Komuta K, Nishikawa M, Gemma A, Yamaki K, Kawahara M, Miyakoshi C, Mio T. Yoshioka H, et al. Among authors: gemma a. Clin Lung Cancer. 2024 Oct 1:S1525-7304(24)00197-9. doi: 10.1016/j.cllc.2024.09.004. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39482146
Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01).
Takeuchi S, Kubota K, Sugawara S, Teramukai S, Noro R, Fujikawa K, Hirose T, Atagi S, Minami S, Iida S, Kuraishi H, Aiba T, Minegishi Y, Matsumoto M, Seike M, Gemma A, Kawahara M; Japan-Multinational Trial Organization (JMTO). Takeuchi S, et al. Among authors: gemma a. Cancer Med. 2023 Apr;12(8):9133-9143. doi: 10.1002/cam4.5652. Epub 2023 Feb 21. Cancer Med. 2023. PMID: 36807519 Free PMC article. Clinical Trial.
A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.
Kogure Y, Saka H, Takiguchi Y, Atagi S, Kurata T, Ebi N, Inoue A, Kubota K, Takenoyama M, Seto T, Kada A, Yamanaka T, Ando M, Yamamoto N, Gemma A, Ichinose Y. Kogure Y, et al. Among authors: gemma a. Clin Lung Cancer. 2018 Sep;19(5):e711-e715. doi: 10.1016/j.cllc.2018.05.005. Epub 2018 May 19. Clin Lung Cancer. 2018. PMID: 29861395 Clinical Trial.
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Ebi N, Inoue A, Kurata T, Okamoto I, Yamaguchi M, Harada T, Seike M, Ando M, Saito AM, Kubota K, Takenoyama M, Seto T, Yamamoto N, Gemma A. Kogure Y, et al. Among authors: gemma a. Lancet Healthy Longev. 2021 Dec;2(12):e791-e800. doi: 10.1016/S2666-7568(21)00255-5. Lancet Healthy Longev. 2021. PMID: 36098037 Free article. Clinical Trial.
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S; Tokyo Cooperative Oncology Group. Kubota K, et al. Among authors: gemma a. Ann Oncol. 2015 Jul;26(7):1401-8. doi: 10.1093/annonc/mdv190. Epub 2015 Apr 23. Ann Oncol. 2015. PMID: 25908605 Free PMC article. Clinical Trial.
Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study.
Kogure Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Saka H, Ebi N, Inoue A, Kurata T, Fujita Y, Nishii Y, Itani H, Endo T, Saito AM, Shibayama T, Yamamoto N, Gemma A. Kogure Y, et al. Among authors: gemma a. JTO Clin Res Rep. 2023 Apr 6;4(6):100514. doi: 10.1016/j.jtocrr.2023.100514. eCollection 2023 Jun. JTO Clin Res Rep. 2023. PMID: 37304652 Free PMC article.
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
Gemma A, Kudoh S, Ando M, Ohe Y, Nakagawa K, Johkoh T, Yamazaki N, Arakawa H, Inoue Y, Ebina M, Kusumoto M, Kuwano K, Sakai F, Taniguchi H, Fukuda Y, Seki A, Ishii T, Fukuoka M. Gemma A, et al. Cancer Sci. 2014 Dec;105(12):1584-90. doi: 10.1111/cas.12550. Cancer Sci. 2014. PMID: 25287435 Free PMC article. Clinical Trial.
Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Sugano T, Seike M, Saito Y, Kashiwada T, Terasaki Y, Takano N, Hisakane K, Takahashi S, Tanaka T, Takeuchi S, Miyanaga A, Minegishi Y, Noro R, Kubota K, Gemma A. Sugano T, et al. Among authors: gemma a. Thorac Cancer. 2020 Apr;11(4):1052-1060. doi: 10.1111/1759-7714.13364. Epub 2020 Feb 25. Thorac Cancer. 2020. PMID: 32096610 Free PMC article.
433 results